(Q53564949)

15 May 2018

title

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. (English)

1 reference

15 May 2018

main subject

phase I clinical trial

0 references

1 reference

1

1 reference

15 May 2018

Ulrik Lassen

4

1 reference

15 May 2018

Josep Tabernero Caturla

7

1 reference

15 May 2018

author name string

Christian Dittrich

2

1 reference

15 May 2018

Rodrigo Dienstmann

3

1 reference

15 May 2018

Wilfried Büchler

5

1 reference

15 May 2018

Holger Martinius

6

1 reference

15 May 2018

publication date

27 March 2015

1 reference

15 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

15 May 2018

volume

75

1 reference

15 May 2018

issue

5

1 reference

15 May 2018

page(s)

1065-1073

1 reference

15 May 2018

https://scigraph.springernature.com/pub.10.1007/s00280-015-2728-5

exact match

0 references

cites work

Frequent EpCam protein expression in human carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

The biology of the 17-1A antigen (Ep-CAM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Dose escalation methods in phase I cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Serum transaminase elevations as indicators of hepatic injury following the administration of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Monoclonal antibody-induced cytokine-release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2728-5

10.1007/S00280-015-2728-5

21 January 2018

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018